Angina Global Market Report 2024: A $13.61 Billion Market in 2028, Registering a Compound Annual Growth Rate (CAGR) of 6.2%
04 sept. 2024 09h26 HE
|
Research and Markets
Dublin, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The "Angina Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.The angina market size has grown strongly in recent years, from...
US Cardiologists Industry Analysis Trends and Forecasts 2024-2029: Rising Obesity and Heart Disease Rates Among U.S. Population Heighten Need for Cardiologist Care
27 août 2024 04h01 HE
|
Research and Markets
Dublin, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The "Cardiologists in the US - Market Size, Industry Analysis, Trends and Forecasts (2024-2029)" report has been added to ResearchAndMarkets.com's...
U.S. Cardiology Procedures Market Analysis Report 2024-2030: Interventional Procedures, Peripheral Vascular Procedures, Heart Rhythm Management Procedures Size, Share & Trends
11 juil. 2024 10h41 HE
|
Research and Markets
Dublin, July 11, 2024 (GLOBE NEWSWIRE) -- The "U.S. Cardiology Procedures Market Size, Share & Trends Analysis Report by Procedures (Interventional Procedures, Peripheral Vascular Procedures,...
MEACOR Secures $15 Million in Series A Funding to Advance Innovative Transcatheter Heart Valve Repair Technology
14 mai 2024 15h19 HE
|
Meacor inc.
MEACOR Secures $15 Million in Series A Funding to Advance Innovative Transcatheter Heart Valve Repair Technology
HealthTab™ Signs Agreement for More Rexall® Pharmacy Locations
04 avr. 2024 07h30 HE
|
Avricore Health Inc.
Avriciore's HelathTab platform for point-of-care testing in pharmacy expands Rexall locations.
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
18 mars 2024 16h05 HE
|
Tenaya Therapeutics, Inc.
Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track to Dose First Patient in RIDGE™-1Phase 1b Clinical Trial of TN-401 for...
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
18 mars 2024 08h30 HE
|
Tenaya Therapeutics, Inc.
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) PKP2 Gene Replacement Therapy Normalized Heart...
Global Cardiology IT Workflow Solutions Research Report 2024: Market to Reach $1.8 Billion by 2030 - Artificial Intelligence (AI) to Revolutionize Cardiology Workflow Management
01 mars 2024 06h16 HE
|
Research and Markets
Dublin, March 01, 2024 (GLOBE NEWSWIRE) -- The "Cardiology IT Workflow Solutions - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Cardiology IT...
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
27 févr. 2024 16h30 HE
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications
26 févr. 2024 08h30 HE
|
Tenaya Therapeutics, Inc.
Highly selective Small Molecule HDAC6 Inhibitor Effectively Reversed Heart Failure and Improved Diastolic Heart Function Alone or in Combination with SGLT2 Inhibitor in Murine Models of Disease ...